Clearsight Advises Huron on the Divestiture of its Life Sciences Business to Oliver Wyman
Clearsight Advisors, Inc. is pleased to announce another successful transaction in its Life Sciences Consulting practice. Clearsight served as the exclusive financial advisor to Huron Consulting Group Inc. (“Huron” or the “Company”) (NYSE: HURN) on the divestiture of its life sciences commercial and R&D strategy, pricing and market access strategy business (the “Life Sciences Business”) to Oliver Wyman, a business of Marsh McLennan (NYSE: MMC). This deal underscores Clearsight’s role as the premier advisor to high-end Life Sciences and Healthcare consultancies.
Huron is a global consultancy serving clients through a combination of business strategy and digital, operational and cultural transformation. Huron’s Life Sciences Business, a part of the Company’s larger Business Advisory segment, provides commercial and R&D strategy as well as pricing and market access strategy solutions to a variety of pharmaceutical, biotechnology, diagnostics and medical device companies. Oliver Wyman is a global management consulting firm specializing in strategy, operations, risk management and organization transformation. Huron’s Life Sciences Business will consolidate into Oliver Wyman’s Health and Life Sciences Practice, expanding the combined entity’s international footprint, life science strategy offerings and client portfolio, thereby creating a world-class leader in the space.
Mark Hussey, President and COO of Huron, said of working with Clearsight, “The Clearsight team has proven to be an invaluable source of knowledge and advice during our long-standing relationship. Our team was impressed with Clearsight’s process during our 2017 acquisition of Innosight, so when it came time to evaluate strategic options for Huron’s Life Sciences Business, Clearsight immediately came to mind. The team’s industry connections and relentless work ethic added significant value to this process, and we are pleased with the successful outcome.”
Clearsight Vice President Tory Steel commented, “Clearsight is proud to have advised Huron on this significant transaction for the Company’s highly respected Life Sciences Business. Huron’s first-class capabilities and depth of knowledge in the sector are a natural fit for Oliver Wyman’s expanding array of services. We are delighted to have helped Huron’s leadership team and the Board achieve Huron’s strategic goals.”
The Clearsight deal team included Joel Kallett, Greg Treger, Tory Steel, Jonathan Holland and Ethan Webster.
For more information on this transaction, see the full press release on Business Wire.